Sandoz shares jumped 6.4% after the pharmaceutical company raised its revenue guidance following strong performance in its biosimilar product line. The Swiss drugmaker's decision to bump up its financial outlook signals confidence in the growing demand for lower-cost alternatives to biologic medicines. Biosimilars have become a key growth driver for Sandoz as healthcare systems worldwide seek to reduce drug spending.

The guidance increase reflects expanding market share in the biosimilar segment, where Sandoz competes with companies like Amgen and Pfizer. Biosimilars are highly similar versions of existing biologic drugs that offer significant cost savings - typically 15-30% less than the original medications. Sandoz's biosimilar portfolio includes versions of popular drugs treating conditions from cancer to autoimmune diseases.

This positive revision comes as the biosimilar market continues to mature globally, with new products launching and more patents expiring on expensive biologics. The company's ability to capitalize on this trend has investors optimistic about future growth. Sandoz's performance in this space could influence other pharmaceutical companies' strategies in developing their own biosimilar offerings.